Isis Pharmaceuticals, Inc. (ISIS) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
May 8, 2014 6:34 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $70 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) following Q1 results and an update on key initiative. Net loss per share of ($0.27) was slightly wider than the consensus estimate of a loss of... More
Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight
May 6, 2014 3:22 PM EDTPiper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $25.60 yesterday.
... More